Real-life experience with nivolumab and pembrolizumab in patients(pts) with advanced non-small cell lung cancer (NSCLC): Efficacy and safety analysis at the University Hospital Zurich

被引：0
|
作者：
Sanoyan, D. Akhoundova [1 ]
Siebenhuner, A. [1 ]
Delaloye, R. [1 ]
Bankel, L. [1 ]
Paulino, T. D. L. [2 ]
Curioni, A. [1 ]
机构：
[1] Univ Hosp Zurich, Med Oncol, Zurich, Switzerland
[2] Univ Zurich, Inst Expt Immunol, Zurich, Switzerland
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
23P
引用
收藏
页码：7 / 7
页数：1
相关论文
共 50 条
  • [31] Alternative Nivolumab (N) Duration and Scheduling in Advanced Non-Small Cell Lung Cancer (aNSCLC): Real-Life Data
    Dudnik, E.
    Moskovitz, M.
    Agbarya, A.
    Kuznetsov, T.
    Shochat, T.
    Urban, D.
    Wollner, M.
    Zer, A.
    Rotem, O.
    Peled, N.
    Bar, J.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S235 - S236
  • [32] Efficacy and Safety of Pembrolizumab (Pembro; MK-3475) for Patients (Pts) With Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC) Enrolled in KEYNOTE-001
    Soria, J. C.
    Flotten, O.
    Horn, L.
    Felip, E.
    Gandhi, L.
    Hui, R.
    Hellmann, M.
    Leighl, N.
    Zhang, J.
    Kondic, A.
    Rangwala, R.
    Lubiniecki, G. M.
    Garon, E. B.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S726 - S727
  • [33] The safety and efficacy of pembrolizumab for the treatment of non-small cell lung cancer
    Mazarico Gallego, Jose Ma
    Herrera Juarez, Mercedes
    Paz-Ares, Luis
    EXPERT OPINION ON DRUG SAFETY, 2020, 19 (03) : 233 - 242
  • [34] Efficacy and Tolerability of Nivolumab in Elderly Patients with Advanced Non-Small Cell Lung Cancer
    Yamane, K.
    Takeda, K.
    Yanai, M.
    Tanaka, N.
    Izumi, H.
    Sakamoto, T.
    Yamaguchi, K.
    Yamasaki, A.
    Igishi, T.
    Eiji, S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1918 - S1918
  • [35] Real world efficacy of nivolumab for non-small cell lung cancer (NSCLC) in the West of Scotland (WoS)
    Ansel, S.
    Rulach, R.
    Clark, B.
    Steele, N.
    Maclaren, V.
    LUNG CANCER, 2018, 115 : S35 - S36
  • [36] Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC)
    Besse, B.
    Garrido Lopez, P.
    Puente, J.
    Cortot, A.
    Olmedo Garcia, M. E.
    Perol, M.
    Gil, M.
    Chao, G.
    Shahidi, J.
    Bennouna, J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [37] Trends in demographics and survival for patients (pts) with advanced non-small cell lung cancer (NSCLC).
    Kubota, K.
    Masuhara, H.
    Hosoya, K.
    Yoh, K.
    Niho, S.
    Goto, K.
    Ohmatsu, H.
    Nishiwaki, Y.
    Saijo, N.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 392S - 392S
  • [38] Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
    Burgos-San Jose, Amparo
    Colomer-Aguilar, Claudia
    Martinez-Caballero, Daniel
    Massuti-Sureda, Bartomeu
    FARMACIA HOSPITALARIA, 2021, 45 (03) : 121 - 125
  • [39] Practical effectiveness efficacy and safety of nivolumab for advanced non-small cell lung cancer: A retrospective multicenter analysis
    Kobayashi, K.
    Nakachi, I.
    Naoki, K.
    Oyamada, Y.
    Nakamura, M.
    Inoue, T.
    Tateno, H.
    Sakamaki, F.
    Sayama, K.
    Terashima, T.
    Koh, H.
    Arai, D.
    Yasuda, H.
    Kawada, I.
    Soejima, K.
    Betsuyaku, T.
    ANNALS OF ONCOLOGY, 2017, 28
  • [40] Safety of nivolumab/pembrolizumab in hepatitis B surface antigen-positive non-small cell lung cancer (NSCLC) patients.
    Xu, Chongrui
    Tu, Hai-Yan
    Sun, Yue-Li
    Li, Yang-Si
    Xu, Bing-Fei
    Wang, Bin-Chao
    Chen, Hua-Jun
    Wang, Zhen
    Zhou, Qing
    Yang, Jin-Ji
    Wu, Yi-Long
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
12345